fig7

Figure 7. Suppressing TNBC TEV release suppresses pulmonary metastasis and improves cancer-related survival. (A) Representative H&E staining from Balb/c WT mice following 4T1-GFP+ tumor resection receiving designated treatment; (B) Quantification of lung area with 4T1-GFP metastasis from mice treated intravenously (iv) with vehicle and given vehicle chow, iv vehicle and reserpine chow, iv injection with 2 mg/kg paclitaxel (twice a week) and vehicle chow, or iv injection with paclitaxel and reserpine chow (n = 8, each group); (C) Flow cytometry analysis of dissociated lung tissue from mice to detect GFP+ cells from WT mice after 4T1-GFP tumor resection exhibiting decreased health condition (n = 3, each group). (D) Kaplan-Meier curve comparing cancer-related survival of WT mice following 4T1-GFP tumor resection treated intravenously (iv) with vehicle and given vehicle chow, iv vehicle and reserpine chow, iv injection with 2 mg/kg paclitaxel (twice a week) and vehicle chow, or iv injection with paclitaxel and reserpine chow (n = 8, each group). Quantitative data are represented as mean ± SEM; P values: * P < 0.05; ** P < 0.01; *** P < 0.001, and ns for not significant from Student’s t test (panels B and C) or log rank test (D). TEVs: Tumor-derived extracellular vesicle; TNBC: Triple-negative breast cancer; WT: wild-type mice; 4T1-GFP: GFP expressing 4T1 murine breast cancer cell line.